Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus NAQUA.
HYDRO-RIDE vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic